v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Company’s Segment

The following table presents the Company’s segment results (unaudited) for the three months ended March 31, 2026 and 2025:

 

                      
  

THREE MONTHS

ENDED MARCH 31, 2026

  

THREE MONTHS

ENDED MARCH 31, 2025

 
  

Medical

Device

  

Digital

Commodities

   Corporate   Consolidated  

Medical

Device

   Corporate   Consolidated 
Net Revenue  $192,780   $-   $-   $192,780   $-   $-   $- 
Cost of goods sold   202,578    -    -    202,578    -    -    - 
Total Cost of Goods Sold   202,578    -    -    202,578    -    -    - 
Gross Margin (Loss)   (9,798)   -    -    (9,798)   -    -    - 
                                    
Staking revenue, net   -    3,134,109    -    3,134,109    -    -    - 
                                    
Operating expenses:                                   
Consulting fees – related parties   -    2,500,000    -    2,500,000    -         - 
Selling, general and administrative   175,488    438,209    4,439,622    5,053,320    427,082    937,214    1,364,296 
Research and development   -    -    137,097    137,097    -    -    - 
Unrealized loss on digital commodities   -    70,846,202    -    70,846,202    -    -    - 
Realized loss on digital commodities   -    10,789,841    -    10,789,841    -    -    - 
Digital commodity transaction expenses   -    63,821    -    63,821    -    -    - 
Total Operating Expenses   175,488    84,638,073    4,576,719    89,390,281    427,082    937,214    1,364,296 
Loss from Operations   (185,286)   (81,503,964)   (4,576,719)   (86,265,970)   (427,082)   (937,214)   (1,364,296)
                                    
Other Income (Expense):                                   
Interest expense, net   -    (19,229)   29,267    10,038    -    (626,991)   (626,991)
Fair market value adjustment on warrants   -    -    16,708    16,708    -    4,618,889    4,618,889 
Foreign currency loss   -    -    (8)   (8)   -    -    - 
Other Income (Expense), net   -    (19,229)   45,967    26,738    -    3,991,898    3,991,898 
Income (Loss) Before Provision for Taxes   (185,286)   (81,523,193)   (4,530,752)   (86,239,232)   (427,082)   3,054,684    2,627,602 
Tax Provision   -    -    -    -              - 
Income (Loss) from Continuing Operations   (185,286)   (81,523,193)   (4,530,752)   (86,239,232)   (427,082)   3,054,684    2,627,602 
                                    
Discontinued Operations:                                   
Loss from discontinued operations   -    -    -    -    (830,769)   -    (830,769)
Income tax benefit   -    -    -    -    132,000    -    132,000 
Loss from Discontinued Operations   -    -    -    -    (698,769)   -    (698,769)
Net Income (Loss)  $(185,286)  $(81,523,193)  $(4,530,752)  $(86,239,232)  $(1,125,851)  $3,054,684   $1,928,833 

 

The following table presents the total assets by segment (unaudited) at March 31, 2026 and December 31, 2025:

 

MARCH 31, 2026   DECEMBER 31, 2025 
Medical Device   Digital Commodities   Corporate   Consolidated   Medical Device   Digital Commodities   Corporate   Consolidated 
$516,543   $174,476,910   $6,009,157   $181,002,610   $849,388   $257,253,661  $10,972,124   $269,075,173 

 

Note: Net Loss by Segment includes Corporate, although not a reportable segment, only for reconciliation to the condensed consolidated statement of operations.